ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?"
Episode Synopsis
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.
More episodes of the podcast GRACEcast Cancer 101 Audio
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31/07/2014
Management of Rare Kidney Tumors
29/07/2014
NanoString Treatment for Kidney Cancer
24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22/07/2014
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/07/2014
What is PD1 and PDL1 in Kidney Cancer?
15/07/2014
In God we trust